MarketWatch

Boltz and Pfizer Announce Strategic Collaboration to Develop and Deploy State-of-the-Art Biomolecular AI Foundation Models

The MarketWatch News Department was not involved in the creation of this content. CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- Pfizer Inc. and Boltz, PBC, an applied AI research lab, today announced ...
GEN

Boltz-2 Released to Democratize AI Molecular Modeling for Drug Discovery

Researchers from the Massachusetts Institute of Technology (MIT) Jameel Clinic for Machine Learning in Health have announced the open-source release of Boltz-2, which now predicts molecular binding ...
Nasdaq

MIT and Recursion Unveil Boltz-2: A Revolutionary Open-Source Biomolecular Co-Folding Model with Advanced Structure and Binding Affinity Prediction

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...
Hosted on MSN

MIT & Recursion Unveil Boltz-2, Accelerates Drug Discovery 1000x, Rivals Physics-Based Accuracy

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks to buy according to hedge funds. Earlier on June 6, a significant advancement in drug discovery was announced with the ...
Nasdaq

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at ...
Hosted on MSN

Pfizer collaborating with Boltz to use AI models for drug discovery

Pfizer (PFE) has entered into an agreement with Boltz to use the latter's biomolecular AI foundation models to tap into the former's historical data "to create state-of-the-art, exclusive models for ...